{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:51:03Z","timestamp":1792450263532,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Cancer antigen 19-9 (CA19-9) is used to assess treatment response among patients with pancreatic ductal adenocarcinoma (PDAC); however, nearly 30% of patients with PDAC do not produce elevated CA19-9.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop, validate, and apply an electronic tumor marker (e19-9) derived from routine laboratory data available in the electronic health record to assess treatment response and predict outcomes among patients with PDAC who do not produce CA19-9.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cohort study, an artificial intelligence (AI) model was trained using routinely collected serum laboratory data from patients with PDAC and elevated CA19-9. The model was externally validated and then applied to a separate cohort of CA19-9 nonproducers. Model development and internal testing were conducted at a single institution using patient data from 2010 to 2022. External validation used a deidentified patient network across 58 health care organizations over the same period. The training cohort included 3239 patients with pancreatic cancer and elevated CA19-9. The external validation cohort included 4384 similar patients. The model was applied to 121 patients with resectable or borderline resectable PDAC who did not produce elevated CA19-9 and received neoadjuvant therapy with curative intent. These data were analyzed from November 2021 through March 2025.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n \n Model performance was assessed using root mean square error and\n R<\/jats:italic>\n 2<\/jats:sup>\n . Clinical outcomes included completion of all neoadjuvant treatment and surgery, metastatic progression, and overall survival (OS).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The final fitted model demonstrated stable performance across both internal and external validation cohorts. Among 121 patients (59 female and 62 male) with localized PDAC who did not produce elevated CA19-9, a 50% or more decline in e19-9 (area under the curve [AUC], 0.79) and e19-9 level of less than 100 (AUC, 0.84) were objectively determined cut points associated with prognosis. A total of 93 patients (77%) completed all planned neoadjuvant therapy and surgery. A 50% or more decline in e19-9 levels and an e19-9 level less than 100 was associated with completion of all intended therapy (odds ratio [OR], 5.00; 95% CI, 1.60-15.66;\n P<\/jats:italic>\n \u2009=\u2009.006 and OR, 19.31; 95% CI, 5.80-64.26;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). An e19-9 level less than 100 was independently associated with OS (hazard ratio, 0.49; 95% CI, 0.25-0.97;\n P<\/jats:italic>\n \u2009=\u2009.04).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n In this study, e19-9 was a noninvasive AI\u2013derived marker that may provide accurate and relevant information to assess treatment response for the approximately 30% of patients with PDAC who do not produce CA19-9 at elevated levels. The development and validation of scalable, noninvasive screening methods using machine-learning algorithms may pave the way for early detection, prognostication, and treatment of cancers.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2026.0291","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:24Z","timestamp":1773847824000},"page":"508","source":"Crossref","is-referenced-by-count":7,"title":["AI\u2013Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1001","volume":"161","author":[{"given":"Sam Z.","family":"Thalji","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aldakkak","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhitya","family":"Ramamurthi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Jaraczewski","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouloud","family":"Belbahri","sequence":"additional","affiliation":[{"name":"Layer 6 AI, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopika","family":"SenthilKumar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Shaik","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Merrill","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjishnu","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley W.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Institute of Southeast Wisconsin, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Kamgar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"George","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Erickson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki K.","family":"Lytle","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. David","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen K.","family":"Christians","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callisia N.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anai N.","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"23","key":"soi260009r1","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"soi260009r2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"issue":"4","key":"soi260009r3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/SLA.0000000000003442","article-title":"Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer.","volume":"273","author":"Perri","year":"2021","journal-title":"Ann Surg"},{"issue":"5","key":"soi260009r4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.pan.2020.05.020","article-title":"Clinical implications of the serum CA19-9 level in \u201cbiological borderline resectability\u201d and \u201cbiological downstaging\u201d in the setting of preoperative chemoradiation therapy for pancreatic cancer.","volume":"20","author":"Takahashi","year":"2020","journal-title":"Pancreatology"},{"issue":"1","key":"soi260009r5","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41598-020-57930-x","article-title":"CA19-9 for detecting recurrence of pancreatic cancer.","volume":"10","author":"Azizian","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"soi260009r6","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1245\/s10434-020-08468-9","article-title":"CA19-9 change during neoadjuvant therapy may guide the need for additional adjuvant therapy following resected pancreatic cancer.","volume":"27","author":"Liu","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"soi260009r7","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdx495","article-title":"Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.","volume":"28","author":"Reni","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"soi260009r8","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1245\/s10434-019-08156-3","article-title":"Serum CA19-9 Response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma.","volume":"27","author":"Al Abbas","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"soi260009r9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.pan.2019.01.023","article-title":"CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.","volume":"19","author":"Li","year":"2019","journal-title":"Pancreatology"},{"issue":"6","key":"soi260009r10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00280-020-04165-2","article-title":"The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.","volume":"86","author":"Ye","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"soi260009r11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer.","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"soi260009r12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/SLA.0000000000003859","article-title":"Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines.","volume":"275","author":"Oba","year":"2022","journal-title":"Ann Surg"},{"issue":"4","key":"soi260009r13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/00000658-199204000-00008","article-title":"Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.","volume":"215","author":"Tian","year":"1992","journal-title":"Ann Surg"},{"issue":"4","key":"soi260009r14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer.","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"issue":"7","key":"soi260009r15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","article-title":"CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.","volume":"20","author":"Hartwig","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"soi260009r16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/archsurg.138.9.951","article-title":"Utility of tumor markers in determining resectability of pancreatic cancer.","volume":"138","author":"Schlieman","year":"2003","journal-title":"Arch Surg"},{"key":"soi260009r17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754687","article-title":"The association of real-world CA 19-9 level monitoring patterns and clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma.","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"soi260009r18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/annonc\/mdw006","article-title":"CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.","volume":"27","author":"Chiorean","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"soi260009r19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/COC.0b013e318280d5f0","article-title":"CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma.","volume":"37","author":"Hayman","year":"2014","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"soi260009r20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3892\/ol.2016.5501","article-title":"Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients.","volume":"13","author":"Luo","year":"2017","journal-title":"Oncol Lett"},{"key":"soi260009r21","doi-asserted-by":"publisher","DOI":"10.1080\/08839510902872223","article-title":"An empirical comparison of techniques for handling incomplete data using decision trees.","author":"Twala","journal-title":"Applied Artificial Intelligence"},{"issue":"1","key":"soi260009r22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40537-021-00516-9","article-title":"A survey on missing data in machine learning.","volume":"8","author":"Emmanuel","year":"2021","journal-title":"J Big Data"},{"key":"soi260009r24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78921","article-title":"Neutrophil-mediated fibroblast-tumor cell il-6\/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: a hybrid clinical-preclinical study.","volume":"11","author":"de Castro Silva","year":"2022","journal-title":"Elife"},{"issue":"10","key":"soi260009r25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ijsu.2013.10.005","article-title":"Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas\u2014a retrospective tumor marker prognostic study.","volume":"11","author":"Distler","year":"2013","journal-title":"Int J Surg"},{"key":"soi260009r26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-94-017-7215-0","article-title":"CA 19-9: biochemical and clinical aspects.","volume":"867","author":"Scar\u00e0","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"soi260009r27","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1245\/s10434-022-13055-1","article-title":"CA19-9 response to first-line neoadjuvant FOLFIRINOX and second-line gemcitabine\/nab-paclitaxel for patients with operable pancreatic cancer.","volume":"30","author":"Thalji","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"soi260009r28","doi-asserted-by":"publisher","first-page":"e2218355","DOI":"10.1001\/jamanetworkopen.2022.18355","article-title":"Adaptive dynamic therapy and survivorship for operable pancreatic cancer.","volume":"5","author":"AlMasri","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"soi260009r29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/jso.25440","article-title":"Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.","volume":"119","author":"Flaum","year":"2019","journal-title":"J Surg Oncol"},{"issue":"20","key":"soi260009r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207651","article-title":"Current status of circulating tumor DNA liquid biopsy in pancreatic cancer.","volume":"21","author":"Grunvald","year":"2020","journal-title":"Int J Mol Sci"},{"key":"soi260009r31","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3389\/fonc.2019.01464","article-title":"Improving treatment response prediction for chemoradiation therapy of pancreatic cancer using a combination of delta-radiomics and the clinical biomarker CA19-9.","volume":"9","author":"Nasief","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"soi260009r32","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"soi260009r33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jso.27265","article-title":"Neoadjuvant chemotherapy for pancreatic cancer: quality over quantity.","volume":"128","author":"Thalji","year":"2023","journal-title":"J Surg Oncol"},{"key":"soi260009r23","unstructured":"Kuhn? M, Wickham? H. Tidymodels: a collection of packages for modeling and machine learning using tidyverse principles. Accessed February 11, 2026. https:\/\/www.tidymodels.org\/"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2846797\/jamasurgery_thalji_2026_oi_260009_1778616108.97221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:01:40Z","timestamp":1778684500000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2846797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2026.0291","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}